Pyxis Oncology (PYXS) Income from Non-Controlling Interests (2023 - 2026)
Pyxis Oncology (PYXS) posted quarterly Income from Non-Controlling Interests of $675000.0 for Q4 2025, down 5.46% year-over-year from $714000.0 in Q4 2024, and down 3.57% quarter-over-quarter from $700000.0 in Q3 2025.
Pyxis Oncology (PYXS) Income from Non-Controlling Interests (2023 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported Income from Non-Controlling Interests for 3 consecutive years, with $675000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Income from Non-Controlling Interests fell 5.46% year-over-year to $675000.0; the TTM figure through Dec 2025 stood at $2.6 million (down 12.15% YoY), while the FY2025 annual figure was $2.6 million, down 12.0% from the prior year.
- Income from Non-Controlling Interests slipped to $675000.0 in Q4 2025 per PYXS's latest filing, from $700000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $799000.0 in Q1 2024 and bottomed at $38000.0 in Q1 2023.
- Historically, Income from Non-Controlling Interests has averaged $606166.7 across 3 years, with a median of $679500.0 in 2025.
- Annual changes were most pronounced in 2024 — Income from Non-Controlling Interests surged 2002.63% — and 2025, when it sank 37.42%.
- Pyxis Oncology's Income from Non-Controlling Interests stood at $600000.0 in 2023, then increased by 19.0% to $714000.0 in 2024, then dropped by 5.46% to $675000.0 in 2025.
- Business Quant data shows PYXS's Income from Non-Controlling Interests at $675000.0 in Q4 2025, $700000.0 in Q3 2025, and $684000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - | 400,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 400,000.00 |
| Dec 31, 2025 | 675,000.00 |
| Sep 30, 2025 | 700,000.00 |
| Jun 30, 2025 | 684,000.00 |
| Mar 31, 2025 | 500,000.00 |
| Dec 31, 2024 | 714,000.00 |
| Sep 30, 2024 | 700,000.00 |
| Jun 30, 2024 | 700,000.00 |
| Mar 31, 2024 | 799,000.00 |
| Dec 31, 2023 | 600,000.00 |
| Sep 30, 2023 | 600,000.00 |
| Jun 30, 2023 | 564,000.00 |
| Mar 31, 2023 | 38,000.00 |